AlphAIalphai — Financial news for AI agents
financialcontent.comJUL 303 min read$OMCL

Omnicell’s (NASDAQ:OMCL) Q2 CY2026: Beats On Revenue But Stock Drops On Weak Guidance

Omnicell (NASDAQ:OMCL) reported Q2 CY2026 revenue of $312.2 million, up 7.4% year on year and 0.6% above Wall Street estimates, and non-GAAP EPS of $0.94, above consensus. For next quarter, it guided revenue to $304 million, below estimates, and guided weaker EPS. The stock fell 5.6% to $39.08.

Original reporting
financialcontent.com
Published Jul 30, 2026, 12:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 30, 2026, 12:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Omnicell’s (NASDAQ:OMCL) Q2 CY2026: Beats On Revenue But Stock Drops On Weak Guidance — source image
Source · financialcontent.com
Decision brief

The 30-second read

$OMCLBearishMed
01

Why it matters

Traders likely reprice the stock around the guidance gap: despite a Q2 beat, the next-quarter revenue outlook is below consensus, and the stock sold off 5.6% immediately after results.

02

Market read

A mixed quarter with a guidance-driven selloff: EPS and revenue beat, but next-quarter revenue guidance underperforms consensus.

03

What to watch

The article notes product segment outperformance and a sharp adjusted operating margin improvement, which may offset the revenue guide if investors extrapolate margins more than top-line.

Relevance 8/10Novelty 6/10Timing: post-Q2 results, immediately after-hours/next-session reaction

Background

Omnicell provides medication management automation and adherence tools, targeting an “Autonomous Pharmacy” model to reduce medication errors.

Company-level read

Ticker impact

$OMCLBearishMedium confidence
Context

Omnicell beat Q2 revenue and adjusted EPS, but guided next-quarter revenue to $304M, below estimates, and shares fell 5.6% to $39.08.

Expected impact

Choppy to bearish near term, with follow-through risk if investors focus on the below-consensus revenue guide rather than the EPS beat.

Evidence & confidence

The article cites a revenue beat and EPS beat, yet the key incremental catalyst is the next-quarter revenue guidance coming in below analysts’ estimates, coinciding with a same-day stock drop.

Market effects

Sector

Signals healthcare automation demand may be uneven, with investors rewarding margin expansion but penalizing revenue visibility.

Regional

No specific regional spillover mentioned.

Global

No global macro or cross-border catalyst mentioned.

Counterpoint

What could challenge this read

Margin and adjusted EPS strength could indicate operating leverage, so the guidance miss may be temporary rather than a structural demand slowdown.

Key entities

  • company
    Omnicell

    Healthcare tech company reporting Q2 CY2026 results and issuing next-quarter revenue guidance.

  • market_reference
    Wall Street estimates

    Analyst consensus figures used to frame the beat/miss on revenue and guidance.

Read at source← All news

Related articles

JUL 30
$OMCLMedAI 8/10

Omnicell (OMCL) Stock Trades Down, Here Is Why

Omnicell (NASDAQ: OMCL) shares fell 9.9% after the company reported Q2 results that beat expectations but issued weaker guidance. Omnicell posted Q2 revenue of $312.2 million and adjusted EPS of $0.94. For Q3, it projected revenue of about $304 million, below estimates, and next-quarter EPS guidance missed consensus.

financialcontent.com4 min
JUL 30
$OMCLHigh

OMNICELL, INC. (OMCL): Results of Operations and Financial Condition

OMNICELL, INC. (OMCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q2-26.htm EX-99.1 Document Exhibit 99.1 Contact: Omnicell, Inc. David Unger 4220 North Freeway Vice President, Investor Relations Fort Worth, TX 76137 ir@omnicell.com Omnicell Announces Second Quarter 2026 Financial Results Omnicell delivers solid second quart

SEC EDGAR 8-K6 min
AUG 9
$HMNMed

Horace Mann Educators Q2 Earnings Call Highlights

Horace Mann (NYSE:HMN) reported Q2 call highlights. Management said auto frequency and severity trends were favorable and liability losses mid-single digits. It cut its full-year catastrophe-loss assumption to about $75M from $90M, while lowering total net investment income outlook to $465M-$475M. Revenue rose 8% YoY; life sales +20%.

yahoo.com6 min
AUG 9
$MURMedAI 8/10

Murphy Oil Sees Sharp Profit Increase

Murphy Oil Corp reported Q2 2026 adjusted net income of $225.8 million, nearly six times Q2 2025, as higher oil prices offset lower production and weaker gas. Adjusted EPS was $1.55 vs $1.51 consensus. Revenue rose to $926.3 million. Murphy kept its $0.35 dividend and raised 2026 capex midpoint to $1.55 billion.

peakoil.com4 min
AUG 9
$GSBDMed

Goldman Sachs BDC Q2 Earnings Call Highlights

Goldman Sachs BDC (NYSE:GSBD) reported no incentive fee in Q2, citing its three-year total-return lookback provision. NAV was $12.06/share at June 30 vs $12.17 in Q1. The board declared a Q3 base dividend of $0.32/share plus $0.03 supplemental. Investments were $3.2B fair value, non-accrual 2.9%, and net debt-to-equity 1.35x.

yahoo.com6 min